Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C43H69N11O3 |
Molecular Weight | 788.0799 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=C(C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCC2=CC=CC=C2)C3=C(N1)C(=CC(=C3)C(C)(C)C)C(C)(C)C
InChI
InChIKey=ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
LTX109 is a synthetic antimicrobial agent and is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner. LTX109 was in clinical phase II trials for topical treatment of infections of multiresistant bacterial strains. However, the further development of this drug apparently has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01158235
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA). Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2% LTX-109/placebo and finally group 3: 5% LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22585222
LTX-109 demonstrated a MIC range of 2 to 4 μg/ml and dose-dependent rapid bactericidal activity against S. aureus.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
HO813QDF65
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
DB12711
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
300000025934
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
25242323
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
1166254-80-3
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
12015
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
DTXSID20151467
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
C188583
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY